BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,079 filers reported holding BAXTER INTL INC in Q3 2019. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $545,218 | -35.0% | 14,447 | -21.5% | 0.06% | -38.0% |
| Q2 2023 | $838,649 | +17.4% | 18,408 | +4.5% | 0.09% | +21.1% |
| Q1 2023 | $714,229 | -20.9% | 17,609 | -0.6% | 0.08% | -26.2% |
| Q4 2022 | $903,297 | -3.9% | 17,722 | +1.5% | 0.10% | -5.5% |
| Q3 2022 | $940,000 | -24.8% | 17,459 | -10.3% | 0.11% | -16.2% |
| Q2 2022 | $1,250,000 | -15.8% | 19,468 | +1.7% | 0.13% | -3.0% |
| Q1 2022 | $1,485,000 | -19.7% | 19,151 | -11.1% | 0.13% | -3.6% |
| Q4 2021 | $1,849,000 | +11.5% | 21,542 | +4.5% | 0.14% | +2.2% |
| Q3 2021 | $1,658,000 | +21.4% | 20,609 | +21.5% | 0.14% | +19.3% |
| Q2 2021 | $1,366,000 | -5.1% | 16,966 | -0.6% | 0.11% | -13.0% |
| Q1 2021 | $1,440,000 | +5.2% | 17,070 | +0.1% | 0.13% | -3.0% |
| Q4 2020 | $1,369,000 | -0.5% | 17,059 | -0.3% | 0.14% | -11.8% |
| Q3 2020 | $1,376,000 | -17.9% | 17,116 | -12.1% | 0.15% | -23.1% |
| Q2 2020 | $1,676,000 | +26.0% | 19,466 | +18.8% | 0.20% | +7.0% |
| Q1 2020 | $1,330,000 | -52.0% | 16,381 | -50.5% | 0.19% | +27.4% |
| Q4 2019 | $2,772,000 | +104.4% | 33,110 | +113.6% | 0.15% | -21.1% |
| Q3 2019 | $1,356,000 | – | 15,499 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |